Unknown

Dataset Information

0

Lactobacillus salivarius UCC118™ Dampens Inflammation and Promotes Microbiota Recovery to Provide Therapeutic Benefit in a DSS-Induced Colitis Model.


ABSTRACT: The use of probiotics such as Lactobacillus and Bifidobacterium spp. as a therapeutic against inflammatory bowel disease (IBD) is of significant interest. Lactobacillus salivarus strain UCC118TM is a commensal that has been shown to possess probiotic properties in vitro and anti-infective properties in vivo. However, the usefulness of UCC118 TM as a therapeutic against colitis remains unclear. This study investigates the probiotic potential of Lactobacillus salivarius, UCC118™ in a mouse model of colitis. DSS-induced colitis was coupled with pre-treatment or post-treatment with UCC118TM by daily oral gavage. In the pre-treatment model of colitis, UCC118TM reduced the severity of the disease in the early stages. Improvement in disease severity was coupled with an upregulation of tissue IL-10 levels and increased expression of macrophage M2 markers. This anti-inflammatory activity of UCC118TM was further confirmed in vitro, using a model of LPS-treated bone marrow-derived macrophages. Taken together, these results suggest that UCC118TM may promote the resolution of inflammation. This was supported in a mouse model of established DSS-induced colitis whereby UCC118TM treatment accelerated recovery, as evidenced by weight, stool, histological markers and the recovery of microbiome-associated dysbiosis with an increased abundance of beneficial commensal species. These results demonstrate the potential of Lactobacillus salivarius UCC118TM as a probiotic-based therapeutic strategy to promote health through the upregulation of anti-inflammatory IL-10 and protect against dysbiosis during IBD.

SUBMITTER: Iyer N 

PROVIDER: S-EPMC9324116 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

<i>Lactobacillus salivarius</i> UCC118™ Dampens Inflammation and Promotes Microbiota Recovery to Provide Therapeutic Benefit in a DSS-Induced Colitis Model.

Iyer Namrata N   Williams Michelle A MA   O'Callaghan Amy A AA   Dempsey Elaine E   Cabrera-Rubio Raul R   Raverdeau Mathilde M   Crispie Fiona F   Cotter Paul D PD   Corr Sinéad C SC  

Microorganisms 20220709 7


The use of probiotics such as <i>Lactobacillus</i> and <i>Bifidobacterium</i> spp. as a therapeutic against inflammatory bowel disease (IBD) is of significant interest. <i>Lactobacillus salivarus</i> strain UCC118<sup>TM</sup> is a commensal that has been shown to possess probiotic properties in vitro and anti-infective properties in vivo. However, the usefulness of UCC118 <sup>TM</sup> as a therapeutic against colitis remains unclear. This study investigates the probiotic potential of <i>Lactob  ...[more]

Similar Datasets

| S-EPMC2394924 | biostudies-literature
| PRJEB53896 | ENA
| S-EPMC3509960 | biostudies-literature
| S-EPMC1863472 | biostudies-literature
| S-EPMC1489637 | biostudies-literature
| PRJNA13280 | ENA
| PRJNA358599 | ENA
| S-EPMC9738729 | biostudies-literature
| S-EPMC10157218 | biostudies-literature
| S-EPMC3028724 | biostudies-literature